Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily

About this episode

The episode discusses Eli Lilly and Boehringer Ingelheim's decision to withdraw over $1 billion in planned investments in Germany.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strategic withdrawal by Eli Lilly and Boehringer Ingelheim from planned investments in Germany. Both c...

People in this episode

Host: Pharma and BioTech News

Topics covered

• pharmaceutical investments
• biotechnology
• strategic business decisions
• regulatory updates
• scientific advancements

Keywords

• Eli Lilly
• Boehringer Ingelheim
• Germany
• pharmaceutical industry
• biotech investments
• strategic withdrawal
• regulatory updates

Mentioned in this episode

Organizations: Eli Lilly, Boehringer Ingelheim

Places: Germany

More episodes of Pharma and BioTech Daily

• Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily · June 12, 2026 · 5 min
• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Legend Biotech's CAR T-Cell Breakthrough: 100% Response Rate | Pharma and Biotech Daily · June 4, 2026 · 6 min